Horus Pharma, an independent French pharmaceutical company specializing in ophthalmology, is reaching a major milestone in its development with the launch of an aflibercept biosimilar indicated for age-related macular degeneration (AMD). By positioning itself in this retinal disease area, which represents a major public health challenge, the company is expanding its expertise into one of the most strategic segments of ophthalmology and now covers the full spectrum of eye diseases, from the most common to the rarest.
Addressing the growing challenges of retinal diseases
Against a backdrop of an aging population, the prevalence of retinal diseases continues to rise, increasing the need for effective and accessible treatments while placing growing pressure on the sustainability of healthcare systems.
The arrival of biosimilars represents a key response to these challenges by broadening access to treatment, maintaining high standards of efficacy and safety, and contributing to better control of healthcare expenditures.
An Aflibercept biosimilar supporting access to care
A pioneer of pragmatic innovation in ophthalmology, Horus Pharma has distinguished itself in recent years through several major advances serving both patients and healthcare professionals, including the first preservative-free hyaluronic acid medical device reimbursed in France for the treatment of dry eye disease, a sustained-release intravitreal implant for diabetic macular edema, as well as dehydrated and freeze-dried amniotic membranes.
With this aflibercept biosimilar, the company continues its commitment to useful and accessible innovation focused on the concrete needs of patients and practitioners. This approach prioritizes solutions capable of improving access to care, expanding available therapeutic alternatives, and addressing public health challenges.
The commercialization of this treatment across all European markets is based on a partnership with the German biopharmaceutical company Formycon, one of the global leaders in biosimilar development.
“With our entry into the AMD treatment market, we are reaching a decisive milestone in Horus Pharma’s development. Already active in the retinal field for the treatment of diabetic macular edema, we are now extending our expertise to a major disease at the heart of public health challenges linked to aging. This development reflects our ambition: to make essential treatments accessible while providing concrete solutions for both patients and healthcare professionals throughout the ophthalmology care pathway,” said Claude Claret, chief executive officer.
A model built on a comprehensive approach to ophthalmology
With a portfolio of more than 70 products covering all ocular diseases, Horus Pharma is deploying a strategy aimed at comprehensively addressing visual health needs. Beyond the most common indications, the company is also committed to segments that remain poorly or insufficiently addressed.
This comprehensive approach meets a dual objective:
- For healthcare professionals, to provide a complete and integrated range of solutions covering a wide variety of clinical situations, with a single partner capable of supporting all their ophthalmology needs.
- For patients, to offer concrete, tailored, and complementary solutions at every stage of the care pathway, including medicines, medical devices, human tissues, dietary supplements, and cosmetics.
By extending its expertise to AMD and integrating biosimilars into its portfolio, the company is strengthening its position as a leading European player in eye health.
